Compare prices and buy Hexarelin from 10 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic hexapeptide, His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2 (C47H58N12O6, CAS 140703-51-1), whose international nonproprietary name is examorelin. It is GHRP-6 with one extra methyl group on the D-tryptophan, reported by Romano Deghenghi's group. It is an agonist at the ghrelin receptor, GHS-R1a, and in healthy young adults released growth hormone about as strongly as GHRP-2, along with prolactin, ACTH and cortisol. Months of repeated administration partially attenuated the growth hormone response, which recovered after treatment stopped. A separate line of preclinical work identified CD36 as a hexarelin binding site in rat heart and found protection against ischemia-reperfusion damage in rats without a pituitary. Not FDA-approved, and absent from FDA's 503A and 503B compounding category lists.
For research purposes only. Not medical advice.
Hexarelin is a synthetic hexapeptide, His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2, with the formula C47H58N12O6 and CAS 140703-51-1. Its international nonproprietary name is examorelin, and FDA's substance registry files the development codes EP-23905 and MF-6003 under the same record.
It is GHRP-6 carrying one extra methyl group, on the D-tryptophan at position 2, a residue its designers chose because 2-methyl-tryptophan is chemically more stable. The two formulas differ by exactly that CH2. Romano Deghenghi's group reported the peptide in rats in 1994 (Deghenghi, Life Sciences, 1994), and a placebo-controlled study in 12 healthy men followed the same year (Imbimbo, European Journal of Clinical Pharmacology, 1994). The GHRP-6 and GHRP-2 pages cover the class's earlier history and its receptor.
Hexarelin is an agonist at the ghrelin receptor, GHS-R1a, the target it shares with GHRP-6, GHRP-2 and ipamorelin. Human findings:
A Europe PMC search in October 2026 found no head-to-head human comparison of hexarelin and GHRP-6. In anesthetized rats the two released growth hormone about equally at every intravenous dose tested (Deghenghi, Life Sciences, 1994).
No published study ranks the growth hormone releasing peptides by how fast this attenuation appears.
A separate line of work, almost all preclinical, concerns the heart.
Neither hexarelin nor examorelin appears in drugsfda as of October 2026. Both names are absent from both tables of FDA's Category 2 page, from the 503A categories list updated May 14, 2026 and from the 503B list updated March 21, 2025, so, unlike GHRP-6 and GHRP-2, it holds no category in either compounding pathway. No Pharmacy Compounding Advisory Committee agenda located since 2016 names it, and ClinicalTrials.gov holds no registration under either name.
Yes. Examorelin is the international nonproprietary name for hexarelin, and FDA's substance registry holds one record for both, under CAS 140703-51-1 with the formula C47H58N12O6 and the development codes EP-23905 and MF-6003. The World Anti-Doping Agency uses examorelin on its prohibited list. Vendor titles vary between Hexarelin, Hexarelin Acetate and Hexarelin (Examorelin), and all three name the same hexapeptide. A listing that says acetate is naming the salt form, which carries less peptide per weighed milligram than the free base.
All three are hexapeptides that act at the ghrelin receptor, GHS-R1a. Hexarelin is GHRP-6 with one methyl group added to its D-tryptophan, a change made for chemical stability, and the two molecular formulas differ by exactly that CH2. In six healthy young adults, hexarelin and GHRP-2 produced similar growth hormone responses, both larger than GHRH's, and similar rises in prolactin, ACTH and cortisol (Arvat, Peptides, 1997). No head-to-head human comparison of hexarelin and GHRP-6 turned up in a Europe PMC search in October 2026, and in anesthetized rats the two released growth hormone about equally.
In the longest human study, 16 weeks of subcutaneous hexarelin in 12 healthy elderly adults, the area under the growth hormone curve fell from 19.1 to 10.5 micrograms per liter per hour and returned to 19.4 four weeks after treatment stopped, which the authors described as a partial and reversible attenuation (Rahim, Journal of Clinical Endocrinology and Metabolism, 1998). Intranasal treatment in short children blunted the response within a week, and it recovered three months after stopping (Klinger, European Journal of Endocrinology, 1996). Courses of 8 to 15 days left the response unchanged. No published study ranks the growth hormone releasing peptides by how fast this happens.
CD36 is a membrane glycoprotein that researchers identified as a hexarelin binding site in rat heart. Hexarelin bound an 84,000-dalton protein in rat cardiac membranes whose N-terminal sequence matched rat CD36, and the rise in coronary perfusion pressure it caused was absent in CD36-null mice and in CD36-deficient rats (Bodart, Circulation Research, 2002). That work is preclinical, as is the finding that hexarelin limited ischemia-reperfusion damage in rats without a pituitary (Locatelli, Endocrinology, 1999). Human studies gave a single acute dose and measured left ventricular ejection fraction, which rose in healthy men, in bypass surgery patients and in patients with ischemic cardiomyopathy, but not in patients with dilated cardiomyopathy.
It has no US approval and no compounding category. As of October 2026, drugsfda holds no application for hexarelin or examorelin, and neither name appears in either table of FDA's page on bulk drug substances that may present significant safety risks, in the 503A categories list updated May 14, 2026 or in the 503B list updated March 21, 2025. That makes hexarelin unusual among the growth hormone releasing peptides, since GHRP-6 and GHRP-2 both appear on the 503A and 503B lists. No Pharmacy Compounding Advisory Committee agenda located since 2016 names it, and ClinicalTrials.gov holds no registration under either name.
Hexarelin is sold by 10 research peptide vendors indexed on PeptideScouter, with 13 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
8 of the 10 indexed vendors currently have Hexarelin in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
ezPeps currently lists Hexarelin at $5.90/mg, the lowest listed price across 10 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $4.72/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 10 vendors listing Hexarelin publish a PeptideScouter code, worth 10% to 20% off. Applied, the lowest effective price falls from $5.90/mg listed to $4.72/mg at ezPeps. Each vendor's code is shown beside its price in the table above.
Hexarelin ranges from $5.90/mg to $14.99/mg across 13 listings from 10 research peptide vendors, normalized to USD per milligram and refreshed daily.
10 research peptide vendors currently list Hexarelin on PeptideScouter, with 8 in stock right now. We track 13 listings across size and kit variants.
Hexarelin's CAS Registry Number is 140703-51-1. It is also sold as Hexarelin Acetate, Hexarelin (Examorelin).
